JP7618950B2 - 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 - Google Patents

免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 Download PDF

Info

Publication number
JP7618950B2
JP7618950B2 JP2021516357A JP2021516357A JP7618950B2 JP 7618950 B2 JP7618950 B2 JP 7618950B2 JP 2021516357 A JP2021516357 A JP 2021516357A JP 2021516357 A JP2021516357 A JP 2021516357A JP 7618950 B2 JP7618950 B2 JP 7618950B2
Authority
JP
Japan
Prior art keywords
antibody
tumor
cells
toxin
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021516357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511337A (ja
JP2022511337A5 (enExample
Inventor
ローレンス，トビー
クラー モーストルップ，ソーレン
エゼロット，アンダース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Original Assignee
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS filed Critical Aix Marseille Universite
Publication of JP2022511337A publication Critical patent/JP2022511337A/ja
Publication of JP2022511337A5 publication Critical patent/JP2022511337A5/ja
Priority to JP2024223694A priority Critical patent/JP2025038162A/ja
Application granted granted Critical
Publication of JP7618950B2 publication Critical patent/JP7618950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2021516357A 2018-09-19 2019-09-18 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 Active JP7618950B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024223694A JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306219.9 2018-09-19
EP18306219 2018-09-19
PCT/EP2019/075080 WO2020058372A1 (en) 2018-09-19 2019-09-18 Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024223694A Division JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Publications (3)

Publication Number Publication Date
JP2022511337A JP2022511337A (ja) 2022-01-31
JP2022511337A5 JP2022511337A5 (enExample) 2022-09-07
JP7618950B2 true JP7618950B2 (ja) 2025-01-22

Family

ID=63787877

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516357A Active JP7618950B2 (ja) 2018-09-19 2019-09-18 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
JP2024223694A Pending JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024223694A Pending JP2025038162A (ja) 2018-09-19 2024-12-19 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Country Status (5)

Country Link
US (1) US20220073638A1 (enExample)
EP (1) EP3853251A1 (enExample)
JP (2) JP7618950B2 (enExample)
CN (1) CN113396160A (enExample)
WO (1) WO2020058372A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025038162A (ja) * 2018-09-19 2025-03-18 インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114423787B (zh) 2019-07-19 2025-01-24 昂科里斯庞斯公司 免疫调节性抗体及其使用方法
WO2021064184A1 (en) * 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CN114694745A (zh) * 2022-03-24 2022-07-01 至本医疗科技（上海）有限公司 预测免疫疗效的方法、装置、计算机设备和存储介质
US20260015419A1 (en) * 2022-07-15 2026-01-15 Whitehead Institute For Biomedical Research Combination of macrophage-directed immunotherapy and cytokines for treatment of cancer
EP4655324A1 (en) 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
WO2025114555A1 (en) 2023-11-30 2025-06-05 Oncospear Aps Anti-cd163 antibodies with improved adcc capabilities
EP4563596A1 (en) * 2023-11-30 2025-06-04 OncoSpear ApS Anti-cd163 antibodies with improved adcc capabilities
WO2025207936A1 (en) * 2024-03-28 2025-10-02 Mirror Biologics, Inc. Treatment for colorectal cancer using immune checkpoint inhibitors
CN120695211A (zh) * 2025-06-25 2025-09-26 广东医科大学附属医院 mRNA组合物及其在制备肝纤维化治疗药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533912A (ja) 2014-10-29 2017-11-16 ファイヴ プライム セラピューティクス インク がんのための併用療法
WO2018156725A1 (en) 2017-02-24 2018-08-30 Thomas Jefferson University Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors
WO2018158658A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US7257268B2 (en) 2003-02-28 2007-08-14 Aperio Technologies, Inc. Systems and methods for image pattern recognition
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
JP4658125B2 (ja) 2005-06-28 2011-03-23 パイオニア株式会社 放送受信装置、妨害検出装置および妨害検出方法
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
US8023714B2 (en) 2007-06-06 2011-09-20 Aperio Technologies, Inc. System and method for assessing image interpretability in anatomic pathology
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP5551702B2 (ja) 2008-09-16 2014-07-16 ヒストロックス，インコーポレイテッド． バイオマーカー発現の再現性のある定量
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
US20110111435A1 (en) 2009-11-06 2011-05-12 SlidePath Limited Detecting Cell Surface Markers
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
EA031470B1 (ru) 2013-03-15 2019-01-31 Бристол-Майерс Сквибб Компани Ингибиторы ido
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
EA029661B1 (ru) 2013-09-06 2018-04-30 Ауриген Дискавери Текнолоджиз Лимитед Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
US10617672B2 (en) * 2015-10-15 2020-04-14 Lipomedix Pharmaceuticals Ltd. Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
ITUB20160191A1 (it) * 2016-01-21 2017-07-21 Invectors S R L Kit per la preparazione di doxorubicina liposomiale funzionalizzata con peptidi per il target selettivo di recettori sovra espressi da cellule tumorali
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
WO2018019990A1 (en) * 2016-07-28 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatement of cancer disease by targetting tumor associated macrophage
CN109790220A (zh) * 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
KR20190092478A (ko) * 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
EP3853251A1 (en) * 2018-09-19 2021-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533912A (ja) 2014-10-29 2017-11-16 ファイヴ プライム セラピューティクス インク がんのための併用療法
WO2018156725A1 (en) 2017-02-24 2018-08-30 Thomas Jefferson University Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors
WO2018158658A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jonas Heilskov Graversen, Soren Kragh Moestrup，Drug Trafficking into Macrophages via the Endocytotic Receptor CD163，Membranes， Vol. 5，228-252，https://www.mdpi.com/2077-0375/5/2/228
Journal of Controlled Release，2012年，Vol.160，pp.72-80

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025038162A (ja) * 2018-09-19 2025-03-18 インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物

Also Published As

Publication number Publication date
US20220073638A1 (en) 2022-03-10
CN113396160A (zh) 2021-09-14
EP3853251A1 (en) 2021-07-28
JP2022511337A (ja) 2022-01-31
WO2020058372A1 (en) 2020-03-26
JP2025038162A (ja) 2025-03-18

Similar Documents

Publication Publication Date Title
JP7618950B2 (ja) 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
JP7129449B2 (ja) ヒト化ｃｃケモカイン受容体４（ｃｃｒ４）抗体およびその使用法
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
CA2851762A1 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
AU2007318483A1 (en) Anti-human Dlk-1 antibody showing anti-tumor activity in vivo
US20240175873A1 (en) Methods for the diagnosis and treatment of t cell-lymphomas
CN113544151A (zh) 抗il-27抗体及其用途
CN108474793A (zh) 预后方法
WO2019089753A2 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
TW202116807A (zh) 用於治療特定患者之癌症的抗體組合
TW202340243A (zh) 抗ｃｄ３９抗體及其用途
JP6159010B2 (ja) テトラスパニン８に対するハイブリドーマクローンおよびモノクローナル抗体
JP6159011B2 (ja) Ｃｄ９に対するハイブリドーマクローンおよびモノクローナル抗体
KR102487356B1 (ko) 종양 관련 대식세포를 표적화하는 항체 및 이의 용도
WO2019199896A1 (en) Agonist antibodies against human cd137 in cancer that express mhc i
WO2024003310A1 (en) Methods for the diagnosis and treatment of acute lymphoblastic leukemia
JP2020507576A (ja) Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
JP2023525053A (ja) 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法
CN117177771A (zh) 一种诊断和治疗t细胞淋巴瘤的方法
EP4508432A1 (en) Methods for the diagnosis and treatment of t-cell malignancies
WO2023198874A1 (en) Methods for the diagnosis and treatment of t cell-lymphomas
WO2024023283A1 (en) Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
JP2016005449A (ja) Ｃｄ９に対するハイブリドーマクローンおよびモノクローナル抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241219

R150 Certificate of patent or registration of utility model

Ref document number: 7618950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150